Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
higher decrease » higher degree (Expand Search), higher degrees (Expand Search), highest increase (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
higher decrease » higher degree (Expand Search), higher degrees (Expand Search), highest increase (Expand Search)
-
81
Image 3_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif
Published 2024“…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”
-
82
Image 1_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif
Published 2024“…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”
-
83
Image 4_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif
Published 2024“…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”
-
84
-
85
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
86
-
87
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
88
-
89
-
90
-
91
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
92
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
93
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
94
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
95
-
96
-
97
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
98
Metabolites with decreasing levels during the development.
Published 2025“…<p>Temporal profiles of polar metabolites and lipids with SCN levels significantly decreasing from E19 to P28. Rhythmicity was determined by eJTK; full or dashed lines depict the profiles that either did or did not pass the significance threshold (FDR-adjusted <i>P</i> < 0.05), respectively.…”
-
99
-
100